NexImmune Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	13	15.93	15.8	10.01	5.71	5.24
Research & Development	19.28	47.15	37.46	17.84	15.17	8
Other Operating Expenses	0.69	0	0	0	0	0
Operating Expenses	32.97	63.08	53.26	27.85	20.89	13.24
Operating Income	-32.97	-63.08	-53.26	-27.85	-20.89	-13.24
Interest Expense / Income	0	0	0.91	1.68	0.01	0
Other Expense / Income	-0.63	-0.58	-3.26	0.33	-0.35	-0.41
Pretax Income	-32.34	-62.51	-50.9	-29.87	-20.55	-12.83
Net Income	-32.34	-62.51	-50.9	-29.87	-20.55	-12.83
Preferred Dividends	0	0	0.38	3.28	2.66	2.07
Net Income Common	-32.34	-62.51	-51.28	-33.15	-23.21	-14.91
Shares Outstanding (Basic)	1	1	1	0	0	0
Shares Outstanding (Diluted)	1	1	1	0	0	0
Shares Change	9.05%	19.19%	1508.68%	1.16%	10.53%	-
EPS (Basic)	-30.82	-64.95	-63.50	-660.50	-467.75	-332.00
EPS (Diluted)	-30.82	-64.95	-63.50	-660.50	-467.75	-332.00
Free Cash Flow	-31.47	-52.37	-48.14	-27.27	-20.66	-12.06
Free Cash Flow Per Share	-29.99	-54.41	-59.62	-543.29	-416.40	-268.56
EBITDA	-30.78	-61.01	-49.13	-27.56	-20.1	-12.63
Depreciation & Amortization	1.56	1.5	0.87	0.62	0.44	0.2
EBIT	-32.34	-62.51	-50	-28.18	-20.54	-12.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).